Shares of Shree Ganesh Remedies Ltd declined sharply by 8.17% on Tuesday, trading at ₹716 on the BSE, down from the previous close of ₹779.70. The steep fall comes in response to weak Q4 FY25 earnings.
For the quarter ended March 2025, the company’s net profit slumped 47.66% year-on-year to ₹6.59 crore, compared to ₹12.59 crore in the corresponding period last year. Revenue from operations also saw a major decline of 34.56%, falling to ₹24.43 crore from ₹37.33 crore.
The company’s operating profit margin (OPM) also contracted to 40.40% from 45.38% in the year-ago quarter, further reflecting margin pressures.
For the full fiscal year, net profit declined 17.93% to ₹23.07 crore from ₹28.11 crore in FY24, while revenue dropped 13.74% to ₹108.60 crore compared to ₹125.90 crore in the previous year.
With a market cap of ₹9.19 billion and a P/E ratio of 32.28, Shree Ganesh Remedies has seen increased volatility amid earnings-driven selling pressure.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
